amifostine

Trade name: ethyol

Small moleculeapprovedOrphan Drug FDA

Approved

Dec 8, 1995

Amifostine is an organic thiophosphate cytoprotective agent known chemically as 2-[(3¬ aminopropyl)amino]ethanethiol dihydrogen phosphate (ester), it’s adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed under the trade name Ethyol. Amifostine is a prodrug and is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. The ability of Ethyol to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure to either cisplatin or radiation. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumor cells. — NCATS

Clinical trial activity

81 trials · 75 clinical orgs · 8 marketing orgs

Phase 1
27
Phase 2
62
Phase 3
8
Phase 4
3

Earliest trial started May 1, 1988 (NCT00003582)

Timeline

1980s

  1. Jan 1, 1988

    Earliest Phase 1 Sponsor(trial)

1990s

  1. May 30, 1990

    Orphan Drug Designation

  2. Jan 1, 1995

    Earliest Phase 2 Sponsor(trial)

  3. Dec 8, 1995

    US Bioscience — Earliest FDA Approval

  4. Dec 8, 1995

    Clinigen — Marketing Organization

  5. Dec 8, 1995

    Cosette — Marketing Organization

  6. Dec 8, 1995

    Clinigene International Ltd — NDA Secondary Org

  7. Dec 8, 1995

    US Bioscience — NDA Organization

  8. Dec 8, 1995

    Clinigen — NDA Secondary Org

  9. Dec 8, 1995

    LEGACY PHARMA — Marketing Organization

  10. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Mar 14, 2008

    Sun Pharmaceuticals — Marketing Organization

2010s

  1. Jul 17, 2017

    Eugia Pharma — Marketing Organization

  2. Jul 17, 2017

    Mylan — Marketing Organization

Indications

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Reactive metabolite scavenging agent

    Prodrug. Scavenge of reactive oxygen species and reactive metabolites of cisplatin

  • Unspecified targetAntioxidant

    Antioxidant

    Prodrug. Scavenge of reactive oxygen species and reactive metabolites of cisplatin

Approval history

  • approvedPriority reviewDec 8, 1995

Chemistry & pharmacology

Loading structure…

SMILES

NCCCNCCSP(O)(O)=O
Mol. weight
214.223 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Prodrug

Sources

Also known as

  • amifostina
  • amifostina
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine
  • amifostine trihydrate
  • amifostine trihydrate
  • amifostine trihydrate
  • amifostinum
  • amifostinum
  • aminopropylaminoethyl thiophosphate
  • aminopropylaminoethyl thiophosphate
  • aminopropylaminoethyl thiophosphate
  • ethiofos
  • ethiofos
  • ethiofos
  • ethyol
  • ethyol
  • ethyol
  • ethyol
  • gammaphos
  • gammaphos
  • gammaphos
  • radprotect
  • wr-2721
  • wr-2721
  • wr-2721

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07192588Phase 2Jul 26, 2024EXCELYA, Graegis Pharmaceuticals Ltd
NCT05230680Phase 1/Phase 2 (Phase 2)May 1, 2022Sungkyunkwan University
NCT03702985Phase 2May 28, 2018Fudan University
NCT02587442Phase 1Oct 1, 2015Original BioMedicals Co. Ltd.
NCT01998529Phase 1Aug 1, 2014University of Texas at Houston
NCT01762514Phase 2Jan 1, 2013Dalian Merro Pharmaceutical Co. Ltd, Sun Yat-Sen University
NCT01586117Phase 2Feb 1, 2012Chinese Academy of Medical Sciences
NCT01288625Phase 4Mar 1, 2011People's Liberation Army of China, Sun Pharmaceuticals
NCT05167370Phase 2Dec 13, 2010Good Samaritan Hospital, Cincinnati, University of Cincinnati
NCT01364259Phase 3Sep 1, 2008Stanford University
NCT00571298Phase 1Nov 1, 2007Harvard University
NCT00409331Phase 2Dec 1, 2006MedImmune, University of Texas at Houston
NCT00601198Phase 2Oct 1, 2006AstraZeneca, MedImmune, University of Cincinnati
NCT00274937Phase 3Feb 1, 2006National Cancer Institute (NCI)
NCT00503776Phase 2Jan 1, 2006National Cancer Institute (NCI), Vanderbilt University
NCT00137358Phase 1Aug 26, 2005MedImmune, University of Alabama, Birmingham
NCT00217438Phase 3Jul 1, 2005National Cancer Institute (NCI), University of Washington
NCT00217542Phase 1Jul 1, 2005National Cancer Institute (NCI), Yale University
NCT00098683Phase 2Jan 1, 2005Johns Hopkins University, National Cancer Institute (NCI), University of New Mexico
NCT00086099Phase 1/Phase 2 (Phase 2)Jul 1, 2004MedImmune
Showing 20 of 81 trials
Page 1 / 5

Organizations

Research & Development (75)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government34941995
MedImmuneFor profit10242002
Harvard UniversityAcademic/Hospital6621998
University of Texas at HoustonAcademic/Hospital4421997
Rush UniversityAcademic/Hospital3321997
University of ArizonaAcademic/Hospital3311997
AlzaFor profit2111997
AstraZenecaFor profit2012003
City of Hope National Medical CenterAcademic/Hospital2121999
European Organisation for Research and Treatment of CancerAcademic/Hospital2211998
Gynecologic Oncology GroupAcademic/Hospital2221998
Mayo ClinicAcademic/Hospital2022001
Northwestern UniversityAcademic/Hospital2121999
Radiation Therapy Oncology GroupAcademic/Hospital2221998
Stanford UniversityAcademic/Hospital2122000
Thomas Jefferson UniversityAcademic/Hospital2221997
University of Alabama, BirminghamAcademic/Hospital2222002
University of California, Los AngelesAcademic/Hospital2211997
University of ChicagoAcademic/Hospital2211996
University of CincinnatiAcademic/Hospital2212006
75 organizations
Page 1 / 4

Marketing (10)

OrganizationOrg typeRelationshipDate
ClinigenFor profitMKTGDec 8, 1995
ClinigenFor profitNDA2Dec 8, 1995
Clinigene International LtdFor profitNDA2Dec 8, 1995
CosetteFor profitMKTGDec 8, 1995
Eugia PharmaFor profitMKTGJul 17, 2017
LEGACY PHARMAFor profitMKTGDec 8, 1995
MylanFor profitMKTGJul 17, 2017
Sun PharmaceuticalsFor profitMKTGMar 14, 2008
Sun PharmaceuticalsFor profitSYNMar 14, 2008
US BioscienceFor profitNDADec 8, 1995